



For Immediate Release

**Virica Biotech to be Showcased in Xtalks Webinar:
Process Intensification in AAV Gene Therapy**

Ottawa, Canada – November 4, 2022 –[Virica Biotech Inc. \(“Virica”\)](#), a leading developer of solutions for scaling of viral medicines, will be featured in a [live webinar](#) to be held on **Monday, November 14, 2022, at 2:30pm EST**. This [webinar](#) will focus on [process intensification in the manufacturing of adeno associated virus \(AAV\) vectors](#).

AAV vectors are critical to gene therapy development. These vectors are the delivery system for inserting good genes into cells. Currently, demand for AAV vectors is rising with more than [550 adeno associated viral vector therapies](#) being developed for the treatment of various disorders. Unfortunately, manufacturers are unable to keep up with demand, as manufacturing AAV-based gene therapies is labor-intensive and costly due to the cell culture production process.

“I’ve spoken with numerous biotech companies with exciting plans to introduce transformative gene therapies, but they are struggling to access financially viable AAV manufacturing yields. In this webinar, I look forward to exploring current and new strategies for optimising the upstream AAV vector production process, a vital first step towards advancing gene therapies to meet clinical and commercial yields.”

- Dr. Jean-Simon Diallo, CEO of Virica Biotech.

[Please join experts](#) Amine Kamen, Ph.D., McGill University; Sarah Wootton, Ph.D., University of Guelph; and Jean-Simon Diallo, Ph.D., Virica Biotech, to discuss opportunities for process intensification in AAV gene therapy and the role of antiviral defences in AAV gene therapy systems.

Tune into [this free webinar](#) to learn about:

- AAV biology and its use in cell and gene therapies
- State-of-the-art production of cell and gene therapies
- Current process intensification methods: cell line and vector engineering, media optimization, and bioreactor design to increase yields
- New strategies to properly attenuate anti-viral defences in the production system: viral sensitizer technology.

About Virica Biotech

Virica optimizes the manufacturing of viral medicines which allows developers to economically deploy their products at scale. Virica’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate anti-viral defenses in manufacturing cells. Customized VSE formulations substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, cell and gene therapies, and anti-cancer therapies. Visit [viricabiotech.com](#) for more information.

-###-



Media Contact:

Jennifer Cameron, Communications, Virica Biotech

T: 1 902 209 4704 / E: Communications@viricabiotech.com

This news release contains "forward-looking statements," which reflect the current expectations of the Company's management for future growth, results of operations, performance and business prospects. Forward-looking statements involve significant known and unknown risks, uncertainties and assumptions.